强化血压控制对2型糖尿病成人认知结局和脑结构的影响:BPROAD随机对照试验次要结局的预设分析。
完整摘要 · 中文译文
目的:评估在成人2型糖尿病患者中,与标准治疗相比,收缩压(SBP)强化治疗对认知结局和大脑结构的影响。 设计:多中心、开放标签、结局评估者设盲、随机对照试验。 地点:中国七个地理区域的145个临床中心。 参与者:12 821名年龄≥50岁、患有2型糖尿病、SBP升高且心血管风险增加的成人,其中12 434名基线时无 probable dementia 者被纳入本认知辅助研究。进一步评估每年进行并在研究结束时进行。 干预:参与者被随机分配接受目标SBP<120 mm Hg的强化治疗或目标SBP<140 mm Hg的标准治疗,最长持续五年。 主要结局指标:主要认知结局为全因痴呆或轻度认知障碍的复合结局。次要认知结局包括全因痴呆、轻度认知障碍、认知功能变化以及脑磁共振成像(MRI)特征变化。一部分参与者在基線时(n=862)和研究结束时(n=605)接受脑MRI,以评估白质病变体积和总脑体积的变化。 结果:6219名参与者被分配接受强化治疗,6215名接受标准治疗。基线平均年龄为63.7岁,5567名(44.8%)参与者为女性。一年后,强化治疗组的平均SBP为121.6 mm Hg,标准治疗组为133.2 mm Hg。Dur 在中位随访3.8年期间,强化治疗组有747名参与者(每100人年3.69起事件)发生了主要认知结局,即全因痴呆或轻度认知障碍,标准治疗组有783名参与者(每100人年3.89起事件)发生该结局(风险比0.96,95%置信区间(CI)0.86至1.06;P=0.38)。在MRI子研究(强化治疗428例 vs 标准治疗434例)中,与标准治疗组相比,强化治疗组的白质病变体积增加较小(组间差异为-0.09反双曲正弦(asinh)转换cm³,95%CI -0.15至-0.02;P=0.01)。 结论:在中位约四年的时间内,在接受收缩压标准治疗(目标<140 mm Hg)和强化治疗(目标<120 mm Hg)的2型糖尿病成人中,未观察到全因痴呆或轻度认知障碍复合结局发生率有统计学显著差异。然而,强化治疗与脑白质病变体积累积减少相关。 试验注册:ClinicalTrials.gov NCT03808311。
完整摘要 · 英文原文
OBJECTIVE: To evaluate the effect of intensive compared with standard treatment of systolic blood pressure (SBP) on cognitive outcomes and brain structures in adults with type 2 diabetes. DESIGN: Multicentre, open label, outcome assessor masked, randomised controlled trial. SETTING: 145 clinical centres across seven geographical regions in China. PARTICIPANTS: 12 821 adults aged ≥50 years with type 2 diabetes, raised SBP, and increased cardiovascular risk, of whom 12 434 without probable dementia at baseline were included in this cognitive ancillary study. Further assessments were performed annually and at the end of study. INTERVENTIONS: Participants were randomly assigned to receive intensive treatment targeting SBP <120 mm Hg or standard treatment targeting SBP <140 mm Hg for up to five years. MAIN OUTCOME MEASURES: The primary cognitive outcome was a composite of all cause dementia or mild cognitive impairment. Secondary cognitive outcomes included all cause dementia, mild cognitive impairment, changes in cognitive functions, and changes in brain magnetic resonance imaging (MRI) characteristics. A subset of participants underwent brain MRI at baseline (n=862) and at the end of study (n=605) to assess changes in white matter lesion volume and total brain volume. RESULTS: 6219 participants were assigned to receive intensive treatment and 6215 to receive standard treatment. Baseline mean age was 63.7 years, and 5567 (44.8%) participants were women. After one year, mean SBP was 121.6 mm Hg in the intensive treatment group and 133.2 mm Hg in the standard treatment group. During a median follow-up of 3.8 years, the primary cognitive outcome of all cause dementia or mild cognitive impairment occurred in 747 participants (3.69 events per 100 person years) in the intensive treatment group and 783 participants (3.89 events per 100 person years) in the standard treatment group (hazard ratio 0.96, 95% confidence interval (CI) 0.86 to 1.06; P=0.38). In the MRI substudy (428 intensive treatment v 434 standard treatment), the intensive treatment group had a smaller increase in white matter lesion volume compared with the standard treatment group (between group difference -0.09 inverse hyperbolic sine (asinh) transformed cm3, 95% CI -0.15 to -0.02; P=0.01). CONCLUSIONS: Over a median of about four years, no statistically significant difference in incidence of a composite of all cause dementia or mild cognitive impairment was observed among adults with type 2 diabetes receiving standard treatment of SBP (target <140 mm Hg) and intensive treatment (target <120 mm Hg). Intensive treatment was, however, associated with a reduction in the accrual of cerebral white matter lesion volume. TRIAL REGISTRATION: ClinicalTrials.gov NCT03808311.